Documentdetail
ID kaart

oai:pubmedcentral.nih.gov:1004...

Onderwerp
Review
Auteur
Caneschi, Alice Bardhi, Anisa Barbarossa, Andrea Zaghini, Anna
Langue
en
Editor

MDPI

Categorie

Antibiotics

Jaar

2023

vermelding datum

21-10-2023

Trefwoorden
veterinary medicine antibiotics resistance
Metriek

Beschrijving

As warned by Sir Alexander Fleming in his Nobel Prize address: “the use of antimicrobials can, and will, lead to resistance”.

Antimicrobial resistance (AMR) has recently increased due to the overuse and misuse of antibiotics, and their use in animals (food-producing and companion) has also resulted in the selection and transmission of resistant bacteria.

The epidemiology of resistance is complex, and factors other than the overall quantity of antibiotics consumed may influence it.

Nowadays, AMR has a serious impact on society, both economically and in terms of healthcare.

This narrative review aimed to provide a scenario of the state of the AMR phenomenon in veterinary medicine related to the use of antibiotics in different animal species; the impact that it can have on animals, as well as humans and the environment, was considered.

Providing some particular instances, the authors tried to explain the vastness of the phenomenon of AMR in veterinary medicine due to many and diverse aspects that cannot always be controlled.

The veterinarian is the main reference point here and has a high responsibility towards the human–animal–environment triad.

Sharing such a burden with human medicine and cooperating together for the same purpose (fighting and containing AMR) represents an effective example of the application of the One Health approach.

Caneschi, Alice,Bardhi, Anisa,Barbarossa, Andrea,Zaghini, Anna, 2023, The Use of Antibiotics and Antimicrobial Resistance in Veterinary Medicine, a Complex Phenomenon: A Narrative Review, MDPI

Delen

Bron

Artikelen aanbevolen door ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw